Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials

Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials

This item appears in the following Collection(s)

Available in accordance with the Publisher Policy. Please refer to the publisher's site for terms of use.

Search Repository


My Account

Statistics